CD40 Activation Protects Dendritic Cells from Anticancer Drug-Induced Apoptosis.
- Author:
Jae Yeon JUN
1
;
Hong Gu JOO
Author Information
1. Department of Veterinary Medicine, Cheju National University, Jeju 690-756, Republic of Korea. jooh@cheju.ac.kr
- Publication Type:Original Article
- Keywords:
Dendritic cells;
CD40 activation;
Apoptosis;
5-FU;
Mitomycin C
- MeSH:
Annexin A5;
Apoptosis*;
Dendritic Cells*;
Down-Regulation;
Drug Therapy;
Fluorescence;
Fluorouracil;
Humans;
Immunosuppression;
Major Histocompatibility Complex;
Mitomycin;
T-Lymphocytes
- From:The Korean Journal of Physiology and Pharmacology
2003;7(5):255-260
- CountryRepublic of Korea
- Language:English
-
Abstract:
Dendritic cells (DCs) play a critical role in various immune responses involving CD4 T cells and have been used to generate anti-tumor immunity. Chemotherapy induces severe side effects including immunosuppression in patients with cancer. Although immunosuppression has been studied, the effects of anticancer drugs on DCs are not fully determined. In this study, we demonstrated that CD40 activation strongly protected DCs from 5-fluorouracil (5-FU) or mitomycin C-induced apoptosis. DC- specific surface markers, including CD11c and major histocompatibility complex (MHC) class II, were used for identifying DCs. CD 40 activation with anti-CD40 mAb significantly enhanced the viability of DCs treated with 5-FU or mitomycin C, assayed by MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide). Fluorescence staining and analysis clearly confirmed the enhancing effect of anti-CD40 mAb on the viability of DCs, suggesting that CD40 activation may transduce critical signals for the viability of DCs. Annexin V staining assay showed that CD40 significantly protected DCs from 5-FU or mitomycin C-induced apoptosis. Taken together, this study shows that CD40 activation with anti-CD40 mAb has strong anti-apoptosis effect on DCs, suggesting that CD40 activation may overcome the immunosuppression, especially downregulation of number and function of DCs in chemotherapy- treated cancer patients.
